Johnson & JohnsonvsNurix Therapeutics

JNJ and NRIX stock compared: price, dividend, valuation and results, from SEC filings.

NRIX

Nurix Therapeutics, Inc.

$14.73

Value $1.6B

-4.84%
NRIX's page

Johnson & Johnson (JNJ) has a market value of $681B and Nurix Therapeutics (NRIX) $1.6B. Over the last year, with dividends, JNJ moved +47.5% and NRIX +15.1%. The P/E is 42.3 for JNJ and 5.5 for NRIX. Dividend yield: JNJ 1.87%, NRIX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$681B

    NRIX$1.6B

    JNJ is 423 times NRIX

  • Revenue, 12 months

    JNJ$99.3B

    NRIX$702M

    JNJ is 142 times NRIX

  • Net income, 12 months

    JNJ$16.1B

    NRIX$295M

    JNJ is 55 times NRIX

  • Operating margin

    JNJ–

    NRIX41.3%

  • ROIC

    JNJ12.4%

    NRIX41.4%

    29.0 points apart

  • P/E

    JNJ42.3

    NRIX5.5

    JNJ is 7.7 times NRIX

  • Dividend yield

    JNJ1.9%

    NRIX0.0%

    1.9 points apart

  • 5-year return

    JNJ+98.6%

    NRIX-56.6%

    155.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+98.6%

NRIX-56.6%

10020020222023202420252026
Returns by period
PeriodJNJWith dividendsNRIXWith dividends
1 year since November 14, 2025+47.5%Price +44.2%+15.1%Price +15.1%
3 years since November 16, 2023+105.0%+27.0% a yearPrice +88.2%+142.7%+34.4% a yearPrice +142.7%
5 years since November 15, 2021+98.6%+14.7% a yearPrice +72.8%-56.6%-15.4% a yearPrice -56.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonNRIXNurix Therapeutics

Valuation

JNJNRIX
Valuation
Price$282.55$14.73
Market value$681B$1.6B
Enterprise value (EV)$708B$509M
P/E42.35.5
P/E, 5-year median21.9–
P/B8.41.7
EV/EBIT39.91.8
Free cash flow yield3.0%23.0%

Results and growth

JNJNRIX
Results and growth
Revenue, 12 months$99.3B$702M
Net income, 12 months$16.1B$295M
Free cash flow, 12 months$20.6B$370M
Earnings per share, 12 months$6.59$2.70
Revenue growth, year on year6.1%53.9%
Revenue growth a year, past+2.7%over 5 years+36.4%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJNRIX
Margins and returns on capital
Gross margin67.6%–
Operating margin–41.3%
Net margin16.2%42.0%
ROIC12.4%41.4%
ROE19.7%53.4%

Balance sheet

JNJNRIX
Balance sheet
Cash$17.2B$1.1B
Total debt$44.7B$65M
Net debt / EBITDA1.1-3.7
Interest cover18.0×–

Dividends and buybacks

JNJNRIX
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or NRIX

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Nurix Therapeutics?

By market value, Johnson & Johnson ($681B) is about 423.1 times Nurix Therapeutics ($1.6B), at today's prices.

How did JNJ and NRIX stock do over the last 5 years?

Since November 15, 2021, JNJ's price moved +72.8% and NRIX's -56.6%. With dividends: JNJ +98.6% (+14.7% a year), NRIX -56.6% (-15.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or NRIX?

The dividend yield at today's price is 1.87% for Johnson & Johnson and none for Nurix Therapeutics. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and NRIX?

At today's price, the P/E is 42.3 for JNJ and 5.5 for NRIX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Nurix Therapeutics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 42.0% for Nurix Therapeutics, and the operating margin – and 41.3%. Revenue was $99.3B and $702M.

Which is the better investment, Johnson & Johnson or Nurix Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.